FDA approval summary: Dalteparin for the treatment of symptomatic venous thromboembolism in pediatric patients

On May 16, 2019, the U.S. Food and Drug Administration (FDA) approved dalteparin sodium for the treatment of symptomatic venous thromboembolism (VTE) to reduce the risk of recurrence in pediatric patients 1 month of age and older. Approval was primarily based on FDA review of a single‐arm trial evaluating dalteparin administered subcutaneous twice daily in 38 pediatric patients with symptomatic VTE. Efficacy was based on the achievement of therapeutic plasma anti‐Xa levels. The FDA concluded that dalteparin has efficacy and acceptable safety for pediatric patients.

[1]  S. Vesely,et al.  American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. , 2018, Blood advances.

[2]  Lingyun Ji,et al.  A multi-institutional registry of pediatric hospital-acquired thrombosis cases: The Children's Hospital-Acquired Thrombosis (CHAT) project. , 2018, Thrombosis research.

[3]  P. Monagle,et al.  Anticoagulation therapy in neonates, children and adolescents. , 2017, Blood cells, molecules & diseases.

[4]  K. Haley.  Neonatal Venous Thromboembolism , 2017, Front. Pediatr..

[5]  V. Radulescu.  Anticoagulation Therapy in Children , 2017, Seminars in Thrombosis and Hemostasis.

[6]  G. Young,et al.  Treatment of Venous Thromboembolism in Pediatric Patients , 2017, Front. Pediatr..

[7]  D. Warad,et al.  A retrospective analysis of outcomes of dalteparin use in pediatric patients: a single institution experience. , 2015, Thrombosis research.

[8]  S. O’Brien,et al.  Multicenter dose‐finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism , 2014, Journal of thrombosis and haemostasis : JTH.

[9]  N. Labropoulos,et al.  Pediatric venous thromboembolism in relation to adults. , 2012, Journal of vascular surgery.

[10]  S. Vesely,et al.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[11]  N. Goldenberg,et al.  Venous thromboembolism in children. , 2010, Hematology/oncology clinics of North America.

[12]  C. Feudtner,et al.  Dramatic Increase in Venous Thromboembolism in Children's Hospitals in the United States From 2001 to 2007 , 2009, Pediatrics.

[13]  H. Büller,et al.  Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. , 2001, The Journal of pediatrics.

[14]  M. Bernstein,et al.  Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE , 1994 .

[15]  M. Bernstein,et al.  Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. , 1994, Blood.

[16]  Boscoe M. Paes,et al.  Development of the Hemostatic System in the Neonate and Young Infant , 1990, The American journal of pediatric hematology/oncology.